Vir Biotechnology (VIR) Net Margin (2018 - 2026)

Vir Biotechnology has disclosed Net Margin across 9 years of filings, most recently posting 433431.03% for Q1 2026.

• Net Margin for Q1 2026 came in at 433431.03%, down 42944142.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 675.36% (up 209368.0% YoY), and the FY2025 annual result was 638.87%, up 6453.0% from the prior year.
• Net Margin came in at 433431.03% for Q1 2026 at Vir Biotechnology, down from 66.99% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 46.81% in Q3 2022 to a low of 433431.03% in Q1 2026.
• The 5-year median for Net Margin is 845.23% (2024), against an average of 31858.58%.
• Across the five-year window, Net Margin jumped 859021 bps in 2022 and tumbled 42944142 bps in 2026, its largest moves.
• Vir Biotechnology's Net Margin stood at 205.63% in 2022, then plunged by 236 bps to 690.85% in 2023, then declined by 22 bps to 845.23% in 2024, then jumped by 92 bps to 66.99% in 2025, then tumbled by 646871 bps to 433431.03% in 2026.
• The last three Net Margin figures came in at 433431.03% (Q1 2026), 66.99% (Q4 2025), and 67975.42% (Q3 2025), per Business Quant data.